Q-omics provides the consensus-scored PALLD-AS1 profile across patient tissues and cancer cell-line models. PALLD-AS1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PALLD-AS1 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, PALLD-AS1 RNA expression shows 10,403 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, UCEC, and PDAC as cancer lineages where PALLD-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PALLD-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PALLD-AS1 survival associations across molecular data types. PALLD-AS1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PALLD-AS1 RNA expression–survival associations across cancer types. High PALLD-AS1 expression shows unfavorable associations in ACC, KIRC, THCA and COAD, but favorable associations in LAML and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PALLD-AS1 RNA expression.
This table summarizes PALLD-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for PALLD-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PALLD-AS1 shows lower tumor expression in THCA and KIRP and higher tumor expression in UCEC and HNSC. The UCEC box plot shows higher PALLD-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.310, t-test p = .035).
This table shows molecular features associated with PALLD-AS1 in patient tissues and cancer cell lines. In patient samples, PALLD-AS1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
